← All trials
NCT05611281
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2022
- Primary completion
- Apr 15, 2023
- Completion date
- Jul 20, 2023
- First posted
- Nov 10, 2022
- Last posted
- Nov 10, 2022
- Enrollment
- 96
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.